Articles with GBCA authors in the peer-reviewed scientific literature

Jeannine M. Salamone, Wanda Lucas, Shelley B. Brundage, Jamie N. Holloway, Sherri M. Stahl, Nora E. Carbine, Margery London, Naomi Greenwood, Rosa Goyes, Deborah Charles Chisholm, Erin Price, Roberta Carlin, Susan Winarsky, Kirsten B. Baker, Julia Maues and Ayesha N. Shajahan-Haq


Advocates bring unique and important viewpoints to the cancer research process, ensuring that scientific and medical advances are patient-centered and relevant. In this article, we discuss the benefits of engaging advocates in cancer research and underscore ways in which both the scientific and patient communities can facilitate this mutually beneficial collaboration.

Gary H. Lyman, Heather Greenlee, Kari Bohlke, Ting Bao, Angela M. DeMichele, Gary E. Deng, Judith M. Fouladbakhsh, Brigitte Gil, Dawn L. Hershman, Sami Mansfield, Dawn M. Mussallem, Karen M. Mustian, Erin Price, Susan Rafte, and Lorenzo Cohen


The Society for Integrative Oncology (SIO) produced an evidence-based guideline on use of integrative therapies during and after breast cancer treatment that was determined to be relevant to the American Society of Clinical Oncology (ASCO) membership. ASCO considered the guideline for endorsement

Nora E Carbine, Liz Lostumbo, Judi Wallace, Henry Ko



Recent progress in understanding the genetic basis of breast cancer and widely publicized reports of celebrities undergoing risk‐reducing mastectomy (RRM) have increased interest in RRM as a method of preventing breast cancer. This is an update of a Cochrane Review first published in 2004 and previously updated in 2006 and 2010.

Wrobel K, Zhao YC, Kulkoyluoglu E, Chen KL, Hieronymi K, Holloway J, Li S, Ray T, Ray PS, Landesman Y, Lipka AE, Smith RL, Madak-Erdogan Z. Mol Endocrinol. 2016 Oct;30(10):1029-1045. Epub 2016 Aug 17.

Most breast cancer deaths occur in women with recurrent, estrogen receptor (ER)-α(+), metastatic tumors. There is a critical need for therapeutic approaches that include novel, targetable mechanism-based strategies by which ERα (+) tumors can be resensitized to endocrine therapies.